4F-EPH

4F-EPH's reuptake inhibition of norepinephrine elevates peripheral catecholamine levels, increasing heart rate and blood pressure. Pre-existing cardiovascular disease substantially increases risk of acute events including myocardial ischemia and stroke.

4F-EPH is expected to produce dose-dependent blood pressure elevation. Pre-existing hypertension compounds this effect, increasing risk of hypertensive crisis, particularly with redosing or polydrug combinations.

Sympathomimetic stimulation from DAT/NET inhibition increases risk of triggering arrhythmias in individuals with pre-existing conduction abnormalities or structural heart disease.

High-dose DAT/NET inhibitors can lower seizure threshold. Individuals with epilepsy or other seizure disorders face increased risk, particularly at strong or heavy doses.

Elevated extracellular dopamine in mesolimbic and mesocortical pathways can trigger paranoia, hallucinations, and delusional thinking, particularly with prolonged use or sleep deprivation. 4F-MPH analog case required antipsychotic treatment (Papa 2019).

DAT inhibition elevates dopamine in reward and executive circuits, which can destabilize mood in bipolar disorder and precipitate manic or mixed episodes.

4F-EPH is expected to undergo CES1-mediated ester hydrolysis in the liver (class inference from methylphenidate). Hepatic impairment could reduce metabolic clearance, leading to increased plasma concentrations and prolonged effects. CES1 genetic polymorphisms (G143E) may also increase exposure.

No animal or human reproductive toxicity studies have been conducted for 4F-EPH. Sympathomimetic cardiovascular effects (vasoconstriction, hypertension) pose theoretical risk to fetal perfusion. Contraindicated by precautionary principle.

Whether 4F-EPH or its metabolites are excreted in breast milk is unknown. Given the compound's lipophilicity and stimulant pharmacology, excretion is plausible. Contraindicated by precautionary principle.

Co-administration of 4F-EPH with any monoamine oxidase inhibitor creates risk of hypertensive crisis from the inability to metabolize the elevated catecholamines produced by reuptake inhibition. This is a well-established class interaction for all DAT/NET inhibitors.

Tramadol inhibits both SERT and NET in addition to mu-opioid agonism. Combined with 4F-EPH's NET inhibition, this produces additive noradrenergic load and serotonin syndrome risk. Serotonin syndrome carries mortality up to 12% in severe cases (Hassamal et al. 2018). DB lists this interaction as lethal.